Menu
Back to User profile » Dr Yuxiang Ma
Papers published by Dr Yuxiang Ma:
Frequency, clinical features and differential response to therapy of concurrent ALK/EGFR alterations in Chinese lung cancer patients
Liu J, Mu Z, Liu L, Li K, Jiang R, Chen P, Zhou Q, Jin M, Ma Y, Xie Y, Xiang J, Li B, Ma Y, Mao X, Zhang L, Zhang T, Wu D
Drug Design, Development and Therapy 2019, 13:1809-1817
Published Date: 23 May 2019
Impact of gefitinib in early stage treatment on circulating cytokines and lymphocytes for patients with advanced non–small cell lung cancer
Sheng J, Fang W, Liu X, Xing S, Zhan J, Ma Y, Huang Y, Zhou N, Zhao H, Zhang L
OncoTargets and Therapy 2017, 10:1101-1110
Published Date: 21 February 2017
Clinical analysis of 50 Eastern Asian patients with primary pulmonary large-cell neuroendocrine carcinoma
Zhang XK, Qin T, Zeng YD, Zhao YY, Hou X, Fang WF, Hong SD, Zhou T, Hu ZH, Yang YP, Ma YX, Xue C, Huang Y, Zhao HY, Zhang L
OncoTargets and Therapy 2015, 8:1219-1227
Published Date: 26 May 2015
Risk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trials
Hong SD, Fang WF, Liang WH, Yan Y, Zhou T, Qin T, Wu X, Ma YX, Zhao YY, Yang YP, Hu ZH, Xue C, Hou X, Chen Y, Huang Y, Zhao HY, Zhang L
OncoTargets and Therapy 2014, 7:1851-1867
Published Date: 7 October 2014
Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC
Wu X, Liang WH, Hou X, Lin Z, Zhao HY, Huang Y, Fang WF, Zhao YY, Wu JX, Yang YP, Xue C, Hu ZH, Zhang J, Zhang JW, Ma YX, Zhou T, Qin T, Zhang L
OncoTargets and Therapy 2013, 6:1481-1491
Published Date: 21 October 2013